Search | OpenScholar

Search results

10 results found

Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma

Publication: Journal Article

Hofman, Damon A, Jorge Ruiz-Orera, Ian Yannuzzi, Rakesh Murugesan, Adam Brown, Karl R Clauser, Alexandra L Condurat, et al. 2024. “Translation of Non-Canonical Open Reading Frames As a Cancer Cell Survival Mechanism in Childhood Medulloblastoma”. Mol Cell 84 (2): 261-76.

Donaxi Madrigal

Person: Research Associate I

Ming Chu

Person: Research Associate III

Editor's Note: Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells

Publication: Journal Article

Berger, Raanan, Phillip G. Febbo, Pradip K. Majumder, Jean J. Zhao, Shayan Mukherjee, Sabina Signoretti, Thirza Campbell, et al. 2024. “Editor’s Note: Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells”. Cancer Research.

Alines Lebron-Torres

Person: Research Associate I

Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies

Publication: Journal Article

Martin-Alonso, Carmen, Shervin Tabrizi, Kan Xiong, Timothy Blewett, Sainetra Sridhar, Andjela Crnjac, Sahil Patel, et al. 2024. “Priming Agents Transiently Reduce the Clearance of Cell-Free DNA to Improve Liquid Biopsies”. Science 383 (6680).

Choushi Wang

Person: Postdoctoral Fellow

I am a postdoctoral associate with a research focus on the tumor microenvironment, investigating strategies to manipulate it for therapeutic benefit.

Jung Won Park

Person: Research Associate I

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Publication: Journal Article

Rauh, Ulrike, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, et al. 2024. “BRD-810 Is a Highly Selective MCL1 Inhibitor With Optimized in Vivo Clearance and Robust Efficacy in Solid and Hematological Tumor Models.”. Nat Cancer.

Jenny Serra-Vinardell

Person: Research Scientist II